



THE UNIVERSITY  
of ADELAIDE

Department of Psychological Medicine  
Women's and Children's Hospital  
North Adelaide, 5006, Australia

November 12 2014

Dr John E. Kraus  
VP, Medicines Development Leader  
GlaxoSmithKline  
P.O. Box 13398  
Research Triangle Park, NC, 27709-3398

Dear Dr Kraus

Thank you for your email dated 8 November 2104, and its attachments (the employee's email request for analysis of the HAM-D mood item, and the resulting SAS statistical analysis).

The email proposing analysis of the HAM-D Depression item is surely not the 'analytical plan' referred to in Clinical Study Report. Once again, can you provide a copy of that plan?

If that plan does not set out the provenance of the K-SADS-L depressed mood item and the CGI 1 or 2, could you also provide documentation that shows when each of these outcome variables were specified?

Yours sincerely

Jon Jureidini  
On behalf of the Study 329 RIAT team

cc James Shannon, Chief Medical Officer, GlaxoSmithKline